Genmab A/S has announced impressive net sales figures for its drug DARZALEX, reaching $4.24 billion in the third quarter of 2026. This significant revenue underscores the drug's strong market demand and the company's effective partnership with Johnson & Johnson.
The announcement, made on October 13, 2026, reveals that net sales in the U.S. accounted for $2.53 billion, while sales in the rest of the world totaled $1.71 billion. Genmab earns royalties on these worldwide net sales, benefiting from its exclusive license agreement with Johnson & Johnson for the development and commercialization of daratumumab.
Background
Genmab A/S is a biotechnology company based in Copenhagen, Denmark, dedicated to improving the lives of patients with cancer and other serious diseases through innovative antibody medicines. The company operates in the pharmaceutical preparations sector (SIC: 2834) and is listed on Nasdaq under the ticker GMAB and on the OTC market as GNMSF.
Founded in 1999, Genmab has developed a strong portfolio of antibody-based therapies and has a robust late-stage clinical pipeline. The company has been at the forefront of antibody research and development, with several approved products in its lineup.
What the Filing Says
The filing states, "Worldwide net trade sales of DARZALEX (daratumumab) totaled USD 4,239 million in the third quarter of 2026." It also notes that Genmab receives royalties on these sales, which include both the intravenous and subcutaneous formulations of the drug.
Impact
This announcement is likely to positively impact Genmab's financial outlook and investor confidence. The impressive sales figures may also influence the competitive landscape within the pharmaceutical preparations sector, as other companies may need to enhance their offerings to compete with Genmab's success.
What's Next
The filing does not say what happens next.